|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
News information
新聞資訊

來自歐洲的邀請 | ELRIG DRUG DISCOVERY 2021

2021-10-20
|
訪問量：

DRUG-DISCOVERY.png

ELRIG Drug Discovery 是歐洲最大的生命科學行業專業人士會議，於 2021 年秋季回歸，以慶祝行業的創新和努力以及分享新的科學成就。今年會議的主題是 "After the Storm: Re-Connect, Re-Invent, Re-Imagine"。hjc黄金城歐洲團隊將參展此次會議，歡迎蒞臨hjc黄金城展台交流互動。

ELRIG’s annual Drug Discovery meeting is Europe’s largest meeting for life sciences industry professionals and return in the autumn of 2021, to celebrate the innovation and efforts of our industry and the scientific successes that we have shared throughout the period of the pandemic.

Welcome to Drug Discovery 2021

hjc黄金城展位號 F15

時間 |19-20 October 2021
地點 |The Exhibition Centre, ACC, Liverpool

Agenda

會議日程

Day 1 –19th October 2021

New Approaches in Infection Biology
Diagnostic Testing and Biomarkers – The New Normal?
Innovations in Chemistry to Discover New Medicines: Approaches to Drugging RNA
Alzheimer's Research UK

DAY 2 – 20th October 2021

Screening Innovation to Enhance Drug Discovery
Innovative Strategies Supporting Drug Discovery
Disruptive Technologies
BPS Opportunities and Challenges of Drugging the Undruggable

Medicilon Service Scope

服務範圍

Medicilon Service Scope.png

hjc黄金城（股票代碼：688202）成立於2004年，總部位於上海，致力於為全球製藥企業、研究機構及科研工作者提供全方位的臨床前新藥研究服務。hjc黄金城的一站式綜合服務以強有力的項目管理和更高效、高性價比的研發服務助力客戶加速新藥研發進程，服務涵蓋醫藥臨床前新藥研究的全過程，包括藥物發現、藥學研究及臨床前研究。

From its inception in 2004, Shanghai MedicilonInc. (STAR Market stock code: 688202.SH) has been committed to providingcomprehensive research and development (R&D) services to pharmaceuticalcompanies, research institutions, and any organizations working in thepreclinical space, with the primary objective of supporting and acceleratingpharmaceutical, biopharmaceutical R&D worldwide.

聯係我們：
郵箱：marketing@yakkaa.com
電話: +86 (21) 5859-1500（總機）
業務谘詢專線：400-780-8018
相關新聞